Anti-infectives company MicuRx raises RMB100M

MicuRx Pharmaceuticals Inc. (Hayward, Calif.) raised RMB100 million ($15.1 million) on Dec. 6 in a private placement led by existing investors Delian Capital and BVCF.

The biotech's lead candidates are contezolid (MRX-1) and contezolid acefosamil (MRX-4). MRX-1 is in Phase III testing in China to treat complicated skin and skin structure infections (cSSSIs). Data from the trial are expected in 2H18, with an NDA submission in China slated for early 2019. The candidate is an oral oxazolidinone antibiotic and analog of linezolid, a bacterial protein biosynthesis inhibitor...